TY  - CONF
AU  - Pérez Valero, Ignacio
AU  - Pasquau, Juan
AU  - Rubio, Rafael
AU  - Ribero, Antonio
AU  - Santos, Jose
AU  - Sanz, Jesus
AU  - Mariño, Ana
AU  - Crespo, Manel
AU  - Hernandez, Jose
AU  - Iribarren, Jose Antonio
AU  - Gutierrez, Felix
AU  - Terron, Alberto
AU  - Esteban, Herminia
AU  - Pérez-Molina, Jose Antonio
PY  - 2014
UR  - http://hdl.handle.net/10668/1872
AB  - INTRODUCTIONDue to their low CNS penetrance, there are concerns about the capacity of non-conventional PI-based ART (monotherapy and dual therapies) to preserve neurocognitive performance (NP).METHODSWe evaluated the NP change of aviremic participants...
LA  - en
PB  - BioMed Central
KW  - Fármacos Anti-VIH
KW  - Trastornos del Conocimiento
KW  - Cognición
KW  - Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Anti-HIV Agents
KW  - Medical Subject Headings::Psychiatry and Psychology::Mental Disorders::Delirium, Dementia, Amnestic, Cognitive Disorders::Cognition Disorders
KW  - Medical Subject Headings::Psychiatry and Psychology::Psychological Phenomena and Processes::Mental Processes::Cognition
TI  - CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study.
TY  - conference presentation
ER  -